Form D · Biotechnology
SYNAPSE BIOMEDICAL INC
Oberlin, OH · CIK 0001273829
Offering snapshot reported Dec 20, 2022 · SEC filing
- Reported sold
- Yet to sell Offering amount: $810K
- Investors reported
- 0 Form D · investor count
- Minimum accepted
- $1.5K Reported outside-investor minimum
- First sale
- Yet to occur As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 20, 2022 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Jan 15, 2010 | Initial | $433,358 | No comparison | 5 | SEC filing |
| Jan 27, 2009 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-468055
Source: Form D, filed Dec 20, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sungho Cho | Director |
| Moustapha Diop | Director, Executive |
| Edgar G Engleman | Director |
| Anthony R Ignagni | Director, Executive |
| John Krystowski | Director |
| Kiyotaka Mori | Director |
| Raymond P Onders | Director |
| Louis Tabickman | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
300 Artino Street
Oberlin, OH, 44074
Oberlin, OH, 44074